ArticleMucosal immunology2013
Cell-mediated reduction of human β-defensin 1: a major role for mucosal thioredoxin.
Article in Mucosal immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Upregulated beta-defensin-1 in murine and human biliary atresia associates with human native liver survival.Scientific reports · 2026Article
- Endoplasmic Reticulum Redoxome: Protein Folding and Beyond.Biochemistry · 2026Review
- The AMP-antibiotic-microbiota triad in IBD: a mechanistic framework for dysregulated antimicrobial defense.Frontiers in immunology · 2026Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Significance of Mast Cell Formed Extracellular Traps in Microbial Defense.Clinical reviews in allergy & immunology · 2022Review
- Rewiring host-microbe interactions and barrier function during gastrointestinal inflammation.Gastroenterology report · 2022Review
- Potent bactericidal activity of reduced cryptdin-4 derived from its hydrophobicity and mediated by bacterial membrane disruption.Amino acids · 2022Article
- Thiol Modifications in the Extracellular Space-Key Proteins in Inflammation and Viral Infection.Frontiers in immunology · 2022Review
- Conformational switches and redox properties of the colon cancer-associated human lectin ZG16.The FEBS journal · 2021Article
- Redox Active Antimicrobial Peptides in Controlling Growth of Microorganisms at Body Barriers.Antioxidants (Basel, Switzerland) · 2021Review
- Significance of Endogenous Antimicrobial Peptides on the Health of Food Animals.Frontiers in veterinary science · 2021Review
- Article
- Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide.Scientific reports · 2019Article
- Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease.Inflammatory intestinal diseases · 2019Article
- Myc-induced nuclear antigen constrains a latent intestinal epithelial cell-intrinsic anthelmintic pathway.PloS one · 2019Article
- Bacterial Periplasmic Oxidoreductases Control the Activity of Oxidized Human Antimicrobial β-Defensin 1.Infection and immunity · 2018Article
- β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile AcidsFrontiers in immunology · 2018Article
- Oxygen metabolism and innate immune responses in the gut.Journal of applied physiology (Bethesda, Md. : 1985) · 2017Review
- Ubiquitously expressed Human Beta Defensin 1 (hBD1) forms bacteria-entrapping nets in a redox dependent mode of action.PLoS pathogens · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human β-defensin 1 (hBD-1) is an antimicrobial peptide expressed by epithelia and hematopoietic cells. We demonstrated recently that hBD-1 shows activity against enteric commensals and Candida species only after its disulfide bonds have been reduced by thioredoxin (TRX) or a reducing environment. Here we show that besides TRX, glutaredoxin (GRX) is also able to reduce hBD-1, although with far less efficacy. Moreover, living intestinal and lymphoid cells can effectively catalyze reduction of extracellular hBD-1. By chemical inhibition of the TRX system or specific knockdown of TRX, we demonstrate that cell-mediated reduction is largely dependent on TRX. Quantitative PCR in intestinal tissues of healthy controls and inflammatory bowel disease patients revealed altered expression of some, although not all, redox enzymes, especially in ulcerative colitis. Reduced hBD-1 and TRX localize to extracellular colonic mucus, suggesting that secreted or membrane-bound TRX converts hBD-1 to a potent antimicrobial peptide in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.